162 related articles for article (PubMed ID: 36966205)
1. Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US.
Maki A; Narukawa M
Ther Innov Regul Sci; 2023 Jul; 57(4):671-677. PubMed ID: 36966205
[TBL] [Abstract][Full Text] [Related]
2. Oncology drug lag in Japan: has it improved over the last decade?
Tachibana Y; Narukawa M
Int J Clin Oncol; 2023 Nov; 28(11):1451-1460. PubMed ID: 37561368
[TBL] [Abstract][Full Text] [Related]
3. Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia.
Noguchi A; Hanaoka H; Uyama Y
Ther Innov Regul Sci; 2022 May; 56(3):523-529. PubMed ID: 35181842
[TBL] [Abstract][Full Text] [Related]
4. Different Development Strategies Affecting Japan's Drug lag between Japan-Based and Foreign-Based Companies.
Hidaka M; Hanaoka H; Uyama Y
Ther Innov Regul Sci; 2024 Jul; 58(4):714-720. PubMed ID: 38575785
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated with Inclusion of Japan in Phase I Multiregional Clinical Trials in Oncology.
Maki A; Narukawa M
Ther Innov Regul Sci; 2024 Jul; 58(4):766-772. PubMed ID: 38652349
[TBL] [Abstract][Full Text] [Related]
6. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
Kawabata-Shoda E; Masuda S; Kimura H
J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
[TBL] [Abstract][Full Text] [Related]
7. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
Maeda H; Kurokawa T
Int J Clin Oncol; 2015 Dec; 20(6):1072-80. PubMed ID: 25837976
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials.
Ushijima S; Matsumaru N; Tsukamoto K
Pharmaceut Med; 2021 Jul; 35(4):253-260. PubMed ID: 34291425
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Pediatric Drug Approval Lag in Japan.
Ueyama E; Kaneko M; Narukawa M
Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
[TBL] [Abstract][Full Text] [Related]
10. The notorious "drug lag" for oncology drugs in Japan.
Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
[TBL] [Abstract][Full Text] [Related]
11. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
Tsuji K; Tsutani K
J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
[TBL] [Abstract][Full Text] [Related]
12. Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study.
Maeda H; Hara A; Ofuchi M; Shingai R; Misumi T; Murai Y
Clin Transl Sci; 2023 Dec; 16(12):2665-2674. PubMed ID: 37815272
[TBL] [Abstract][Full Text] [Related]
13. A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers.
Yamashita K; Kaneko M; Narukawa M
Clin Pharmacol Ther; 2019 Jan; 105(1):153-160. PubMed ID: 29882302
[TBL] [Abstract][Full Text] [Related]
14. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
Nakayama H; Matsumaru N; Tsukamoto K
Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
[TBL] [Abstract][Full Text] [Related]
15. Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017.
Lee SW; Park SH; Song I; Noh Y; Park H; Ha D; Shin JY
Ther Innov Regul Sci; 2020 Mar; 54(2):418-423. PubMed ID: 32072585
[TBL] [Abstract][Full Text] [Related]
16. Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis.
Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
Clin Pharmacol Ther; 2021 May; 109(5):1265-1273. PubMed ID: 33048367
[TBL] [Abstract][Full Text] [Related]
17. Utilization of the Bridging Strategy for the Development of New Drugs in Oncology to Avoid Drug Lag.
Kogure S; Koyama N; Hidaka S
J Clin Pharmacol; 2017 Nov; 57(11):1479-1490. PubMed ID: 28628225
[TBL] [Abstract][Full Text] [Related]
18. An Empirical Analysis of Japan's Drug Development Lag Behind the United States.
Nakamura H; Wakutsu N; Murayama S; Suzuki T
J Clin Pharmacol; 2022 Jul; 62(7):847-854. PubMed ID: 34970781
[TBL] [Abstract][Full Text] [Related]
19. International oncology drug approvals for multiregional or single-country clinical trials: A systematic review.
Zhang M; Onakpoya I; Rupalla K
Front Med (Lausanne); 2022; 9():1084980. PubMed ID: 36590932
[TBL] [Abstract][Full Text] [Related]
20. Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States.
Cho I; Han E
Int J Environ Res Public Health; 2022 Mar; 19(5):. PubMed ID: 35270550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
